Status:
COMPLETED
Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure
Lead Sponsor:
University Hospital Ostrava
Conditions:
ARDS
COVID-19
Eligibility:
All Genders
18-80 years
Brief Summary
A monocentric observational study evaluates the accuracy of anticoagulation monitoring in critically ill patients on ECLS (extracorporeal life support) using new markers of the effect of direct thromb...
Detailed Description
Anticoagulation using a direct thrombin inhibitor, argatroban, is one of the modern options for anticoagulation in patients on VV (veno-venous) ECMO (extracorporeal membrane oxygenation) support, and ...
Eligibility Criteria
Inclusion
- Patients with COVID-19
- ARDS according to the Berlin definition
- Veno-venous (VV) ECMO
- Full coagulation with Argatroban or heparin to an anti-FIIa value of 0.4-1.5 or aPTT 50-60
Exclusion
- \- age under 18 years
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06038682
Start Date
April 1 2020
End Date
December 31 2023
Last Update
March 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia, 70852